HAI-ROBOTICS
27.12.2021 10:09:04 CET | Business Wire | Press release
HAI ROBOTICS , a global leader in Autonomous Case-handling Robotics (ACR) systems for warehouse order fulfillment, is celebrating its fifth anniversary at its new headquarters as it ranks among global unicorns according to this year’s unicorn ranking list from the Hurun Research Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211226005013/en/
The company, a logistics warehousing automation solution provider that secured three rounds of funding in 2021, was nominated along with 300 other Chinese start-ups which were valued at more than US$1 billion as of November this year in a global list totaling 1,058. The list was released last week.
HAI ROBOTICS was founded in late 2016 by a group of like-minded robot enthusiasts who aspire to create value for every warehouse and factory with the vision to push forward human civilization through robotics technology. The company’s birth originated from a revolutionary idea that took shape as early as 2015 – the totes-to-person solution – to improve warehouse operational efficiency, instead of creating a homogenous brand of the then prevalent shelves-to-person material handling.
The solution underwent repeated tests and trials in a real warehouse environment for nearly two years before it was formally introduced into the market. The company’s first project was successfully deployed in Best Logistics’ warehouse in August 2018. Soon the story went viral with great exemplary effect that the ACR solution swiftly secured footholds in factories and warehouses.
“It’s an extraordinary journey for us to grow from the cradle of a small workshop into a company of more than 1,200 employees with five branch offices across the globe today,” said Richie Chen, the company’s founder and CEO. “We’re celebrating our fifth anniversary with gratitude to our customers and investors for their trust and confidence in our team. We’ll keep making innovative products and stay committed to bringing value to our partners.”
Automating a warehouse can be a huge project worthy of careful consideration for any business operator. The concerns could range from the length of necessary deployment time, agility of refitting, affordability to ROIs. The HAI ROBOTICS team kept their users’ concerns in mind when building their products. Hence, they kept refining their ideas and fine-tuning the HAIPICK robots for wider applications and stricter storage requirements.
First and foremost, the HAIPICK ACR solution allows greater space utilization and higher goods-handling precision and efficiency than traditional Goods-to-Person solutions, such as Kiva robots that move an entire rack. With the HAIPICK ACR solution, a warehouse’s storage density can be boosted by 80% to 400% and a worker’s picking speed can be improved 3 to 4 times. In addition, the HAIPICK robots, using QR codes on the floor for navigation, can be deployed within one month with no altering of the interior structure of a warehouse.
Thanks to its easy deployment and flexibility, the solution has been adopted by a wide array of customers who prefer smaller picking units than an entire rack or pallet when automating their warehouses. So far, HAI ROBOTICS has been running more than 300 projects globally in various fields, including e-commerce, 3PL, apparel, electronics, energy, manufacturing, medicine, and more. To provide localized service overseas, it has partnered with dozens of global logistics and supply chain leaders, including LG CNS, MHS, MUJIN, BPS, Savoye, Invar, SSI Schaefer and more.
About HAI ROBOTICS
HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.
The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211226005013/en/
Link:
Social Media:
https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
